Your browser is no longer supported. Please, upgrade your browser.
ICPT Intercept Pharmaceuticals, Inc. monthly Stock Chart
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-12.89 Insider Own2.80% Shs Outstand24.06M Perf Week5.18%
Market Cap3.36B Forward P/E- EPS next Y-14.51 Insider Trans-1.47% Shs Float17.45M Perf Month-7.86%
Income-313.70M PEG- EPS next Q-3.73 Inst Own78.50% Short Float20.00% Perf Quarter24.32%
Sales1.80M P/S1868.66 EPS this Y29.90% Inst Trans2.19% Short Ratio6.09 Perf Half Y-18.10%
Book/sh19.94 P/B7.01 EPS next Y12.20% ROA-46.10% Target Price232.83 Perf Year-46.77%
Cash/sh23.15 P/C6.04 EPS next 5Y7.00% ROE-50.40% 52W Range89.76 - 285.00 Perf YTD-6.39%
Dividend- P/FCF- EPS past 5Y-59.20% ROI- 52W High-50.67% Beta-2.27
Dividend %- Quick Ratio5.80 Sales past 5Y- Gross Margin- 52W Low56.64% ATR6.23
Employees405 Current Ratio5.80 Sales Q/Q-71.40% Oper. Margin- RSI (14)54.27 Volatility3.88% 4.68%
OptionableYes Debt/Eq0.00 EPS Q/Q-191.10% Profit Margin- Rel Volume0.66 Prev Close139.80
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume573.06K Price140.60
Recom2.10 SMA201.02% SMA501.13% SMA200-8.21% Volume183,640 Change0.57%
Apr-08-16Downgrade Morgan Stanley Equal-Weight → Underweight
Apr-05-16Upgrade Wells Fargo Market Perform → Outperform
Mar-30-16Initiated Goldman Neutral
Mar-30-16Initiated Credit Suisse Outperform $200
Feb-24-16Reiterated Wedbush Outperform $493 → $423
Dec-04-15Initiated Wells Fargo Market Perform
Nov-18-15Reiterated Oppenheimer Outperform $375 → $375
Nov-11-15Reiterated FBR Capital Mkt Perform $273 → $192
Oct-28-15Downgrade BofA/Merrill Neutral → Underperform
Aug-13-15Initiated Morgan Stanley Underweight $165
May-21-15Initiated Barclays Overweight $425
May-19-15Downgrade BofA/Merrill Buy → Neutral
Apr-17-15Initiated UBS Buy $465
Mar-17-15Initiated MLV & Co Hold $273
Jan-28-15Reiterated Oppenheimer Outperform $499 → $375
Dec-04-14Initiated Robert W. Baird Outperform $258
Dec-03-14Reiterated FBR Capital Underperform $125 → $99
Nov-10-14Reiterated FBR Capital Underperform $172 → $125
Aug-15-14Initiated FBR Capital Underperform $172
Aug-12-14Reiterated RBC Capital Mkts Outperform $425 → $500
May-25-16 11:02AM  Gilead (GILD) Shares Spike After Executive Board Appointment
08:35AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ICPT-US : May 25, 2016
May-24-16 07:30AM  Adaptimmune Strengthens Board with Appointment of Barbara Duncan GlobeNewswire
May-23-16 10:49AM  2 Hotly Debated Drugs Due For FDA Decisions This Week
May-18-16 01:04PM  INTERCEPT PHARMACEUTICALS INC Financials
11:00AM  Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016 GlobeNewswire
May-10-16 05:44PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
May-09-16 08:26AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : May 9, 2016
May-06-16 03:59PM  Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Lag
12:36PM  3 Biotech Stocks Buoyed By Potential Blockbuster Drugs
12:36PM  3 Biotech Stocks Buoyed By Potential Blockbuster Drugs at Investor's Business Daily
May-05-16 11:47PM  Edited Transcript of ICPT earnings conference call or presentation 5-May-16 9:00pm GMT
05:15PM  Intercept reports 1Q loss
04:40PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financ
04:05PM  Intercept Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
07:07AM  Q1 2016 Intercept Pharmaceuticals Inc Earnings Release - After Market Close CCBN
May-04-16 02:04PM  Ioniss Metabolic Segment: Phase I and Phase II Studies Market Realist -5.57%
11:25AM  Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More Zacks
May-03-16 10:43AM  Intercept (ICPT): Stock Likely to Disappoint in Q1 Earnings Zacks
06:31AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events EDGAR Online
Apr-28-16 04:45PM  Intercept to Report First Quarter 2016 Financial Results on May 5 GlobeNewswire
Apr-16-16 07:00AM  Intercept Announces Winners of Practice to Policy Health Awards Program to Encourage New Research and Improve Care for People Living with PBC GlobeNewswire
Apr-15-16 06:07PM  Intercept Pharmaceuticals Reports Phase III Data on Ocaliva
Apr-14-16 09:30AM  The Zacks Analyst Blog Highlights: Intercept, Clovis, AbbVie, Relypsa and Horizon Pharma
07:00AM  New Analyses of the Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC Presented at EASL GlobeNewswire
Apr-11-16 03:15PM  Mid-Cap News: Intercept Rose on Accelerated Approval of Ocaliva -7.50%
Apr-08-16 11:18PM  Last Week's Best Healthcare ETF at Motley Fool
03:35PM  Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote
12:52PM  Intercept Pharma (ICPT) Stock Slips, Downgraded at Morgan Stanley at TheStreet
11:54AM  Intercept Pharma Drops On Downgrade, Despite FDA Panels Yes Vote
10:30AM  Investors Are Buzzing About These 5 Morning Movers at Insider Monkey
09:56AM  Intercept Pharmas Shares Spike Before Falling On Key FDA Panel Backing at Fortune
07:46AM  Early movers: YHOO, ULTA, CBS, LNKD, MET & more at CNBC
06:49AM  Intercept Pharma downgraded by Morgan Stanley
06:07AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Apr-07-16 06:03PM  FDA Panel Backs Approval of Liver-Disease Drug at The Wall Street Journal
05:56PM  Intercept shares rally on FDA panel vote for liver drug at MarketWatch
05:38PM  FDA panel backs speedy approval for Intercept's liver drug Reuters
05:00PM  FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva (obeticholic acid) for the Treatment of PBC GlobeNewswire
03:55PM  FDA panel backs speedy approval of Intercept's liver drug Reuters
09:30AM  The Zacks Analyst Blog Highlights: Gilead, Regeneron, Medivation and Intercept
Apr-06-16 02:08PM  Biotech Stock Roundup: Gilead's HIV Drug Approved, Regeneron Up on Positive Data +8.27%
11:10AM  Intercept (ICPT) Up Ahead of Advisory Committee Meeting
10:08AM  Anacor Pharmaceuticals: $250 Million in Convertible Senior Notes
Apr-05-16 05:51PM  Why Lumber Liquidators, SolarCity, and Intercept Pharmaceuticals Jumped Today at Motley Fool +13.30%
04:50PM  Gilead Descovy Wins FDA Nod, To Buy Nimbus Liver Program
02:18PM  Pfizer leaning toward ditching Allergan deal
12:48PM  Why Intercept Pharmaceuticals (ICPT) Stock is Spiking Today at TheStreet
09:03AM  FDA staff finds Intercept's liver drug effective as monotherapy Reuters
Apr-04-16 01:21PM  Gilead Sciences Broadens Liver Program With Nimbus Acquisition
08:50AM  Gilead Bolsters Liver Disease Pipeline with Nimbus Drug Purchase at TheStreet
Apr-03-16 09:00AM  Biotech Stock Mailbag: Intercept, Acadia, Keryx, Galena at TheStreet
Mar-30-16 04:10PM  Intercept Pharmaceuticals (ICPT) Stock Gets 'Outperform' Rating at Credit Suisse at TheStreet
01:23PM  Intercept Pharma Gets Dueling Initiation Reports As FDA Panel Nears
07:10AM  Intercept Announces New OCA Data in PBC and NASH to be Presented at EASL 2016 at noodls
07:00AM  Intercept Announces New OCA Data in PBC and NASH to be Presented at EASL 2016 GlobeNewswire
Mar-16-16 08:15AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : March 16, 2016
07:00AM  Intercept Pharmaceuticals to Study the Role of Gut Microbiota in the Treatment of Non-Viral Liver Diseases by Obeticholic Acid GlobeNewswire
Mar-14-16 12:40PM  Biotech Mid-Caps Update: Alnylam Rose on Start of ALN-Go1 Trial
Mar-07-16 08:07AM  XBIs Mid-Cap Stocks Outperformed Large Caps
Mar-04-16 08:20AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ICPT-US : March 4, 2016
07:14AM  5 Stocks Poised for Big Breakouts at TheStreet
Mar-02-16 07:00PM  Lightning Round: Two ways to win with this play at CNBC
Feb-29-16 08:09PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
Feb-25-16 08:00AM  Can You Make Money With These Biotech Stocks? VNDA, ICPT, PTLA, and ACOR Accesswire
Feb-24-16 04:27PM  Intercept Pharmaceuticals (ICPT) Stock Price Target Cut at JMP Securities at TheStreet -5.73%
03:17PM  Intercept Pharmaceuticals, Inc. Value Analysis (NASDAQ:ICPT) : February 24, 2016
11:41AM  Intercept Pharmaceuticals, Inc. Earnings Analysis: 2015 By the Numbers
10:30AM  Intercept (ICPT) Q4 Loss Wider Y/Y, Focus on Liver Drug
Feb-23-16 04:37PM  Edited Transcript of ICPT earnings conference call or presentation 23-Feb-16 1:00pm GMT
08:35AM  Intercept (ICPT) Posts Wider-Than-Expected Loss in Q4
08:18AM  Intercept reports 4Q loss
07:31AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:07AM  Q4 2015 Intercept Pharmaceuticals Inc Earnings Release - Before Market Open
07:05AM  Intercept Pharmaceuticals Reports 2015 Financial Results and Provides Business Update GlobeNewswire
Feb-22-16 04:19PM  IBB Posts Impressive Weekly Gains -5.36%
08:02AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : February 22, 2016
Feb-19-16 05:00PM  What's in Store for Intercept (ICPT) This Earnings Season?
Feb-18-16 09:30AM  The Zacks Analyst Blog Highlights: Incyte, Intercept Pharma, Gilead, Aegerion and Clovis
Feb-17-16 05:30PM  Intercept to Report 2015 Full Year Financial Results on February 23 and Present at Upcoming Conference GlobeNewswire +5.42%
05:01PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles o
10:06AM  Biotech Stock Roundup: Incyte Down on Jakafi Update, Is Intercept a Buyout Target?
Feb-16-16 05:00PM  Intercept Pharmaceuticals (ICPT) Soars on Buyout Rumors
01:01PM  Intercept and the Biotech Hail Mary at Bloomberg
Feb-13-16 04:30PM  Last Week's Best Healthcare ETF at Motley Fool
08:38AM  3 Upcoming FDA Decisions We're Most Excited About at Motley Fool
Feb-12-16 03:39PM  Why Intercept Pharmaceuticals Inc is Skyrocketing Today at Motley Fool +27.50%
03:30PM  Intercept Pharma Spikes On Report That Its Exploring A Sale
02:05PM  Intercept Soars on Report of Potential Acquisition Suitors at Bloomberg
02:04PM  Intercept Pharmaceuticals (ICPT) Stock Soars on Sale Talk at TheStreet
Feb-06-16 09:40AM  1 Company Gilead Sciences Should Consider Buying Right Now at Motley Fool
Feb-04-16 04:05PM  Intercept to Present at Upcoming Investor Conferences GlobeNewswire
Feb-03-16 12:00AM  Seven $1 billion-plus drugs seen reaching market in 2016 Reuters
Jan-29-16 11:11AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers +6.96%
08:56AM  Morgan Stanley Upgrades Intercept Pharma, Maintains $100 Target
Jan-27-16 06:03AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Jan-07-16 12:16PM  Intercept Pharmaceuticals Sold Off in December, and Here's Why at Motley Fool
Jan-05-16 11:36AM  Stick With Biotech in 2016? at Barrons.com
11:21AM  The Top 5 Mid-Cap Biotechnology Stocks for 2016 (ALNY, ICPT) at Investopedia
Dec-23-15 02:48PM  Biotech Stock Roundup: KaloBios Removes CEO Shkreli, Actelion PAH Drug Approved
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid, a bile acid analog, that completed Phase III clinical trials for the treatment of primary biliary cholangitis and Phase II clinical trials for the treatment of nonalcoholic fatty liver disease; and is in Phase III clinical trials for the treatment of nonalcoholic steatohepatitis, Phase II clinical trials for the treatments of primary sclerosing cholangitis, and Phase II clinical trial for the treatment of biliary atresia. The company is also developing INT-767, an orally administered dual FXR and TGR5 agonist, which is in Phase I clinical trial for the treatment of fibrosis; and INT-777, an orally administered TGR5 agonist that is in preclinical stage for the treatment of type 2 diabetes. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McMinn RachelChief Strategy OfficerMay 02Sale147.4913019,17414,087May 04 09:00 PM
Pruzanski MarkCEO & PresidentApr 04Sale130.7670892,578548,248Apr 06 09:02 PM
Shapiro DavidCMO and EVP - DevelopmentApr 04Sale130.7616521,57548,546Apr 06 09:02 PM
McMinn RachelChief Strategy OfficerApr 04Sale130.7610413,59914,217Apr 06 09:01 PM
Bright LisaSee RemarksApr 04Sale130.7615320,00619,106Apr 06 09:01 PM
Duncan Barbara GayleChief Financial OfficerApr 04Sale130.7614418,82930,948Apr 06 09:00 PM
Bright LisaSee RemarksFeb 25Sale115.2224127,76819,259Feb 29 09:00 PM
McMinn RachelChief Strategy OfficerFeb 01Sale103.5612813,2567,621Feb 03 09:00 PM
McMinn RachelChief Strategy OfficerJan 04Sale145.9046968,4297,749Jan 05 09:01 PM
Pruzanski MarkCEO & PresidentJan 04Sale145.902,126310,191529,556Jan 05 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJan 04Sale145.9053377,76740,911Jan 05 09:00 PM
Duncan Barbara GayleChief Financial OfficerJan 04Sale145.9046868,28324,892Jan 05 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentDec 18Option Exercise17.5011,426199,99139,821Dec 22 10:00 AM
Shapiro DavidCMO and EVP - DevelopmentDec 15Option Exercise8.673,50030,33331,895Dec 17 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentDec 15Sale157.403,500550,90028,395Dec 17 09:00 PM
Bright LisaSee RemarksNov 25Sale182.961,150210,40912,428Nov 30 09:00 PM
WILLIAMS NICOLEDirectorNov 20Option Exercise9.829739,5571,935Nov 23 09:01 PM
WILLIAMS NICOLEDirectorNov 20Sale167.00973162,491962Nov 23 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentNov 16Option Exercise8.673,50030,33332,659Nov 18 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentNov 16Sale178.534,264761,23728,395Nov 18 09:00 PM
VEITINGER KLAUS R DRDirectorNov 10Option Exercise21.501,00021,5003,166Nov 12 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentNov 10Option Exercise8.673,50030,33332,659Nov 12 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentNov 10Sale204.153,500714,52529,159Nov 12 09:00 PM
VEITINGER KLAUS R DRDirectorNov 10Sale198.251,000198,2502,166Nov 12 09:01 PM
McMinn RachelChief Strategy OfficerNov 02Sale160.2412520,0298,218Nov 04 09:00 PM
AKKARAJU SRINIVASDirectorOct 28Option Exercise21.501,25026,8759,892Oct 30 11:59 AM
WILLIAMS NICOLEDirectorOct 20Option Exercise9.829749,5671,936Oct 22 09:00 PM
WILLIAMS NICOLEDirectorOct 20Sale182.22974177,482962Oct 22 09:00 PM
Pruzanski MarkCEO & PresidentOct 02Sale159.0416726,560526,814Oct 05 09:01 PM
Duncan Barbara GayleChief Financial OfficerOct 02Sale159.04548,58824,062Oct 05 09:02 PM
Duncan Barbara GayleChief Financial OfficerOct 01Option Exercise8.671,0008,66723,818Oct 05 09:02 PM
Duncan Barbara GayleChief Financial OfficerOct 01Sale163.391,000163,39024,116Oct 05 09:02 PM
WILLIAMS NICOLEDirectorSep 21Option Exercise9.829739,5571,935Sep 23 09:00 PM
WILLIAMS NICOLEDirectorSep 21Sale194.82973189,560962Sep 23 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentSep 15Option Exercise8.678,79476,21527,027Sep 17 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentSep 15Sale191.283,500669,48023,527Sep 17 09:00 PM
VEITINGER KLAUS R DRDirectorSep 09Option Exercise21.5050010,7502,666Sep 11 09:00 PM
VEITINGER KLAUS R DRDirectorSep 09Sale198.2550099,1252,166Sep 11 09:00 PM
WILLIAMS NICOLEDirectorAug 20Option Exercise9.829749,5671,936Aug 24 09:00 PM
WILLIAMS NICOLEDirectorAug 20Sale206.85974201,472962Aug 24 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentAug 17Option Exercise8.673,50030,33322,505Aug 19 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentAug 17Sale209.374,272894,42918,233Aug 19 09:00 PM
VEITINGER KLAUS R DRDirectorAug 03Option Exercise21.5050010,7502,666Aug 05 09:00 PM
VEITINGER KLAUS R DRDirectorAug 03Sale261.17500130,5852,166Aug 05 09:00 PM
McMinn RachelChief Strategy OfficerJul 31Sale262.0912733,2864,293Aug 04 09:02 PM
Fundaro PaoloDirectorJul 24Sale285.00582165,8708,221Jul 24 09:12 PM
WILLIAMS NICOLEDirectorJul 20Option Exercise9.829739,5571,935Jul 22 09:00 PM
WILLIAMS NICOLEDirectorJul 20Sale279.01973271,477962Jul 22 09:00 PM
Pruzanski MarkCEO & PresidentJul 10Option Exercise8.6712,500108,334519,514Jul 14 09:00 PM
Pruzanski MarkCEO & PresidentJul 10Sale250.0012,5003,125,000507,014Jul 14 09:00 PM
Adorini LucianoChief Scientific OfficerJul 06Option Exercise21.294,06786,58114,776Jul 08 09:00 PM
Adorini LucianoChief Scientific OfficerJul 06Sale579.934,0672,358,59110,709Jul 08 09:00 PM
Pruzanski MarkCEO & PresidentJul 02Sale236.2615837,328507,014Jul 07 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJul 02Sale236.29851201,08319,005Jul 07 09:00 PM
Duncan Barbara GayleChief Financial OfficerJul 02Sale236.265312,52218,768Jul 07 09:00 PM
Duncan Barbara GayleChief Financial OfficerJul 01Option Exercise8.671,0008,66718,523Jul 06 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJul 01Option Exercise8.673,50030,33322,014Jul 06 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJul 01Sale238.663,781902,37818,233Jul 06 09:00 PM
Duncan Barbara GayleChief Financial OfficerJul 01Sale242.101,000242,10017,523Jul 06 09:00 PM
WILLIAMS NICOLEDirectorJun 22Option Exercise9.829749,5671,936Jun 24 09:00 PM
WILLIAMS NICOLEDirectorJun 22Sale265.14974258,246962Jun 24 09:00 PM
VEITINGER KLAUS R DRDirectorJun 10Option Exercise21.503918,4072,557Jun 12 09:00 PM
VEITINGER KLAUS R DRDirectorJun 10Sale238.2139193,1402,166Jun 12 09:00 PM
Adorini LucianoChief Scientific OfficerJun 08Option Exercise8.674,00034,66714,060Jun 10 09:00 PM
Adorini LucianoChief Scientific OfficerJun 08Sale248.404,000993,59810,060Jun 10 09:00 PM
Pruzanski MarkCEO & PresidentJun 03Option Exercise17.766,561116,550502,304Jun 05 09:00 PM